BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 30400214)

  • 1. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces.
    Huang H
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ALK receptor in sympathetic neuron development and neuroblastoma.
    Janoueix-Lerosey I; Lopez-Delisle L; Delattre O; Rohrer H
    Cell Tissue Res; 2018 May; 372(2):325-337. PubMed ID: 29374774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for ligand reception by anaplastic lymphoma kinase.
    Li T; Stayrook SE; Tsutsui Y; Zhang J; Wang Y; Li H; Proffitt A; Krimmer SG; Ahmed M; Belliveau O; Walker IX; Mudumbi KC; Suzuki Y; Lax I; Alvarado D; Lemmon MA; Schlessinger J; Klein DE
    Nature; 2021 Dec; 600(7887):148-152. PubMed ID: 34819665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC).
    Golding B; Luu A; Jones R; Viloria-Petit AM
    Mol Cancer; 2018 Feb; 17(1):52. PubMed ID: 29455675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism for the activation of the anaplastic lymphoma kinase receptor.
    Reshetnyak AV; Rossi P; Myasnikov AG; Sowaileh M; Mohanty J; Nourse A; Miller DJ; Lax I; Schlessinger J; Kalodimos CG
    Nature; 2021 Dec; 600(7887):153-157. PubMed ID: 34819673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatan sulphate is an activating ligand of anaplastic lymphoma kinase.
    Machino M; Gong Y; Ozaki T; Suzuki Y; Watanabe E; Imagama S; Kadomatsu K; Sakamoto K
    J Biochem; 2021 Dec; 170(5):631-637. PubMed ID: 34270745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anaplastic lymphoma kinase as a therapeutic target.
    Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
    Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.
    Guan J; Umapathy G; Yamazaki Y; Wolfstetter G; Mendoza P; Pfeifer K; Mohammed A; Hugosson F; Zhang H; Hsu AW; Halenbeck R; Hallberg B; Palmer RH
    Elife; 2015 Sep; 4():e09811. PubMed ID: 26418745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
    Roskoski R
    Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
    Webb TR; Slavish J; George RE; Look AT; Xue L; Jiang Q; Cui X; Rentrop WB; Morris SW
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):331-56. PubMed ID: 19275511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma.
    Emdal KB; Pedersen AK; Bekker-Jensen DB; Lundby A; Claeys S; De Preter K; Speleman F; Francavilla C; Olsen JV
    Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
    Li R; Morris SW
    Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
    Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
    Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
    J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.
    Guan J; Wolfstetter G; Siaw J; Chand D; Hugosson F; Palmer RH; Hallberg B
    Oncotarget; 2017 Feb; 8(7):11566-11578. PubMed ID: 28030793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformational Transition of Key Structural Features Involved in Activation of ALK Induced by Two Neuroblastoma Mutations and ATP Binding: Insight from Accelerated Molecular Dynamics Simulations.
    He MY; Li WK; Zheng QC; Zhang HX
    ACS Chem Neurosci; 2018 Jul; 9(7):1783-1792. PubMed ID: 29638111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.
    Murray PB; Lax I; Reshetnyak A; Ligon GF; Lillquist JS; Natoli EJ; Shi X; Folta-Stogniew E; Gunel M; Alvarado D; Schlessinger J
    Sci Signal; 2015 Jan; 8(360):ra6. PubMed ID: 25605972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Mar; 117():343-356. PubMed ID: 28077299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
    Mesaros EF; Ott GR; Dorsey BD
    Expert Opin Ther Pat; 2014 Apr; 24(4):417-42. PubMed ID: 24476492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NUMB regulates the endocytosis and activity of the anaplastic lymphoma kinase in an isoform-specific manner.
    Wei R; Liu X; Voss C; Qin W; Dagnino L; Li L; Vigny M; Li SS
    J Mol Cell Biol; 2019 Dec; 11(11):994-1005. PubMed ID: 30726988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.